Antibody-drug conjugates (ADCs) have emerged as one of the most impactful therapeutic advances in modern oncology, fundamentally reshaping the treatment landscape across both hematologic malignancies ...

The team’s strategy—called antibody–ADC click—relies on the rapid ligation between trans‑cyclooctene (TCO) and tetrazine ...

Detailed price information for Beyondspring Inc (BYSI-Q) from The Globe and Mail including charting and trades.

GSK signed an exclusive licence deal with Hansoh Pharma in 2023, laying out up to $1.71bn in an upfront payment plus ...

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

This collection of articles and expert perspectives explores the critical challenges shapingADC development today, from ...

The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line ...

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in ...

Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need This collaboration further validates ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based ...

July 15, 2026) - Frost & Sullivan has officially released the "Global Antibody Drug Industry Development Blue Book 2026". The Blue Book provides a systematic overview of the current landscape and ...